Q1 2022 Results

Company overview Financial performance CRM Financial review Immunology Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Cosentyx® - IL-17A inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication NCT03713619 SUNSHINE (CAIN457M2301) Hidradenitis Suppurativa (HS) Phase 3 471 Proportion of participants with Hidradenitis Suppurativa clinical response (HiSCR) Secukinumab 300 mg every 2 weeks Secukinumab 300 mg every 4 weeks Placebo (every 2 weeks) Placebo (every 4 weeks) Patients with moderate to severe Hidradenitis Suppurativa Primary (week 16): H2-2021; Final: H2-2022 Study design SHSA 2020; Primary H2-2022 NCT03713632 SUNRISE (CAIN457M2302) Hidradenitis Suppurativa (HS) Phase 3 471 Proportion of patients with Hidradenitis Suppurativa Clinical Response (HiSCR) Secukinumab 300 mg every 2 weeks Secukinumab 300 mg every 4 weeks Placebo (every 2 weeks) Placebo (every 4 weeks) Subjects with moderate to severe Hidradenitis Suppurativa Primary (week 16): H2-2021; Final: 2022 Study design SHSA 2020; Primary 2022 58 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation